Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
CanSino Biologics, Inc. Class H ( (HK:6185) ) has shared an update.
CanSino Biologics Inc. has announced a board meeting scheduled for October 27, 2025, to review and approve the company’s third quarterly results for the period ending September 30, 2025. This meeting is crucial for stakeholders as it will provide insights into the company’s financial performance and strategic direction.
The most recent analyst rating on (HK:6185) stock is a Buy with a HK$66.60 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a biotechnology company based in China, focusing on the development and production of vaccines. The company is known for its innovative approaches in the biopharmaceutical industry, particularly in vaccine development.
Average Trading Volume: 2,301,521
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.9B
Find detailed analytics on 6185 stock on TipRanks’ Stock Analysis page.